Navigation Links
Cardiome Announces Positive Interim Phase 2b Results for Oral Vernakalant and Engages Merrill Lynch as Strategic Advisor
Date:3/17/2008

statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments expressed or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: we may not be able to successfully develop and obtain regulatory approval for vernakalant (iv) or vernakalant (oral) in the treatment of atrial fibrillation or any other current or future products in our targeted indications; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangeme
'/>"/>
SOURCE Cardiome Pharma Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Cardiome And Astellas Announce Regulatory Update
2. Cardiome to Hold Investor Update Call
3. Cardiome Updates Guidance
4. Cardiome Initiates Phase 1 Study for GED-aPC
5. Cardiome To Release Third Quarter Results
6. Cardiome to Present at CIBC Conference
7. Cardiome to Present at ThinkEquity Conference
8. Cardiome to Present at Bear Stearns Conference
9. Weight Watchers Announces Election of Kim Roy to Board of Directors
10. MedQuist Announces Entry Into Settlement Term Sheet Resolving South Broward Litigation
11. Exelixis Announces March 19 Webcast of Presentation at the Lehman Brothers Annual Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 17, 2014 In its latest blog post, ... believes that having family close by during a stay in ... the process is successful, is highlighting a member of the ... the lives of addicts across the country and around the ... can reduce the blood pressure, heart rate, and stress levels ...
(Date:9/17/2014)... sound like the ideas of a science fiction ... an exciting new approach to imaging local and ... prostate cancer, scientists at Virginia Commonwealth University Massey ... Johns Hopkins Medical Institutions have provided proof-of-principle of ... doctors, ability to see tumors that have metastasized ...
(Date:9/17/2014)... NY (PRWEB) September 17, 2014 In ... acknowledges that “bi-weekly telephonic discovery conferences would be beneficial ... such conferences through mid-December. “At the end of December,” ... assess the need for additional conferences. , “The ... recognizes that there is still much to be discussed ...
(Date:9/17/2014)... Dennis Thompson HealthDay Reporter ... in the womb to household chemicals known as phthalates ... Columbia University researchers reported in a new study. ... developing asthma between age 5 and 11 if their ... two phthalates (pronounced thal-ates), the researchers found. The two ...
(Date:9/17/2014)... The Scripps Research Institute (TSRI) have devised a ... effective against vancomycin-resistant strains of MRSA and other ... to have not one but two distinct mechanisms ... evolve resistance quickly. , "This is the prototype ... in clinical use a generation or maybe even ...
Breaking Medicine News(10 mins):Health News:Latest Best Drug Rehabilitation Blog Post Highlights How Dogs are Helping Addicts Recover 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 3Health News:Transvaginal Mesh Lawsuit News: New Order in C.R. Bard MDL Sets Schedule of Conferences for September to December, the Rottenstein Law Group LLP Reports 2Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 2Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 3Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 4Health News:Scripps Research Institute chemists modify antibiotic to vanquish resistant bacteria 2Health News:Scripps Research Institute chemists modify antibiotic to vanquish resistant bacteria 3
... ST. PAUL / MINNEAPOLIS (April 29, 2008) Young ... sexual partners both online and offline have greater numbers of partners, ... rates than those who meet their partners exclusively online or offline, ... ...
... return of members, money to UHW-W,treasury from outside fund, ... local union United Healthcare Workers West (UHW-W) violated federal,law ... millions,of dollars in dues money to an outside fund ... today by SEIU in United States District,Court for the ...
... opportunities for buyer to, capitalize on ... YORK, April 29 Berkery Noyes announced today ... sale to HMP,Communications, a portfolio company of Alta ... investment in the new combined entity. Terms,of the ...
... levels increasing even within normal range associated with dangers ... of thyrotropin within the normal range may increase the ... Norwegian study finds. , Thyrotropin, a hormone produced by ... acts on the thyroid gland to stimulate its growth ...
... (ACP) -- the nations second-largest medical society , ... a continuing medical education (CME) meeting for general ... primary and subspecialty care to adult patients. More ... professionals, medical residents, fellows, and students. Internal Medicine ...
... Baptist Health System, one,of Alabama,s largest healthcare ... to bring together the health-improvement,needs of local employers ... its four hospitals. Aegis brings nearly 20 years, ... with the unique,healthcare needs of area employees., ...
Cached Medicine News:Health News:U of M study: Online intervention paramount for reducing HIV in high-risk population 2Health News:Top UHW-W Officers Violated Federal Law, Deceived Members in Diverting Millions in Dues Money to Outside Fund 2Health News:Top UHW-W Officers Violated Federal Law, Deceived Members in Diverting Millions in Dues Money to Outside Fund 3Health News:Top UHW-W Officers Violated Federal Law, Deceived Members in Diverting Millions in Dues Money to Outside Fund 4Health News:Berkery Noyes Represents Princeton Media Associates in Its Sale to HMP Communications/Alta 2Health News:Berkery Noyes Represents Princeton Media Associates in Its Sale to HMP Communications/Alta 3Health News:Pituitary Hormone May Boost Women's Heart Risk 2Health News:Internal Medicine 2008 media advisory 2Health News:Alabama's Baptist Health System and Aegis Health Group Partner to Address Local Employers Health-Management Concerns 2
(Date:9/17/2014)... YORK , Sept. 17, 2014  Levi & ... in connection with possible claims of breaches of fiduciary ... To get more information, click here: ... you. If you own common stock in ... please contact Eduard Korsinsky, Esq. either via ...
(Date:9/17/2014)... , Sept. 17, 2014 /PRNewswire-iReach/ -- ... white paper discussing improvements in the development ... structures for both normal and diseased tissue ... information, simplifies surgical procedures, lowers surgical costs ... surgical procedures. The clinical ...
(Date:9/17/2014)... , Sept. 17, 2014 Bronstein, Gewirtz & ... purchasers of the securities of PDL BioPharma, Inc. ("PDL ... -News).  Such investors are advised to contact Peretz ... Kimelman at info@bgandg.com or 212-697-6484. ... certain of its executives violated federal securities laws. ...
Breaking Medicine Technology:Patient Outcomes Improve When Molecular Chemical Imaging Technology Is Used to Aid Robotic Surgical Procedures, According to New White Paper 2Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Investigates claims on behalf of Investors of PDL BioPharma, Inc. --PDLI 2
The Eppendorf Maxipettor is a continuously adjustable pipette for precise pipetting of volumes up to 10 ml (in 10 l increments). Even liquids with a high vapor pressure or viscosity can be pipetted w...
... The Repeater Plus, a handheld manual ... saving time on long series pipetting. Its ... exceptional support for research tasks, and its ... with repetitive work. The nine Combitips allow ...
eValuator fixed-curve diagnostic electrophysiology catheters offer an effective balance between clinical performance and cost....
The True Non-Compliant Balloon....
Medicine Products: